The Integrin αvß3 is one of the earliest studied integrins and was found to be expressed in several tumors e.g. glioma, lung cancer brain metastases, prostate cancer or pancreatic cancer. The αvβ3 integrin receptors can be targeted by peptides containing the RGD sequence. For example, Dota-RGD-Dimer Acetate, which can be used both as a potential therapeutic agent and as a diagnostic agent. ABX has several RGD peptides for labelling with radiometals in its catalogue (e.g. ABX prod. no. 9863 for the corresponding monomer or 9804 for the corresponding NODAGA-RGD Dimer).
Learn more about this compound and send us your quote request:
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
